WIWimolsiri Iamsumang

Wimolsiri Iamsumang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wimolsiri Iamsumang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Kumutnart Chanprapaph

    Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Poonkiat Suchonwanit

    Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    3 shared publications
  • Suthinee Rutnin

    Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    3 shared publications
  • Napapat Pongbangpho

    Division of Dermatology , Department of Medicine , Faculty of Medicine , King Chulalongkorn Memorial Hospital , Bangkok , Thailand , chulalongkornhospital.go.th

    2 shared publications
  • Penpun Wattanakrai

    From the Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    2 shared publications
  • Pichamon Promsena

    Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    2 shared publications

Latest Publications

  • Open Access

    Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review

    by Nawara Sakpuwadol, Suthinee Rutnin, Wimolsiri Iamsumang, Kumutnart Chanprapaph

    Drug-induced bullous pemphigoid (BP) is an increasingly recognized variant of BP with unique challenges in management, particularly when patients require continuation of the offending medication or are contraindicated to conventional immunosuppressive therapies. We report 4 patients with drug-induced BP, three associated with dipeptidyl peptidase-4 inhibitors and one with immune checkpoint inhibitor, successfully treated with dupilumab. All four patients had failed or were intolerant to conventional therapies. Following dupilumab initiation, all patients experienced significant improvement in pruritus within 2 weeks. Complete remission was achieved in 3 patients within 1– 5 months of treatment and one patient had stable disease, enabling him to resume pembrolizumab therapy for esophageal cancer while on dupilumab. No significant adverse effects were reported during treatment periods. Our findings, supported by a literature review, suggest that dupilumab demonstrates promising efficacy and safety in treating drug-induced BP, with rapid improvement in pruritus and resolution of skin lesions. It may offer a valuable therapeutic alternative as a steroid sparing agent for elderly patients with multiple comorbidities and provides the potential to continue necessary medications (eg, cancer therapy) that may have triggered BP.


  • Open Access

    NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases

    by Koramon Phuwaraks, Wimolsiri Iamsumang, Kunlawat Thadanipon, Chonlaphat Sukasem, Thawinee Jantararoungtong, Siwaporn Raksa, Vasanop Vachiramon, Nawara Sakpuwadol, Napapat Pongbangpho, Kumutnart Chanprapaph

    Background: While thiopurine S‐methyltransferase (TPMT) variants are known to correlate with azathioprine (AZA)‐induced adverse effects (AEs), nucleoside diphosphate‐linked moiety X Motif 15 (NUDT15) variants were reported to be more prevalent and correlated with AZA toxicity in Asians. However, the information of association between these genetic variants in immune‐mediated skin diseases (IMSDs) is limited. Objective: To evaluate the prevalence of NUDT15 and TMPT genetic variants and their association with AZA‐induced AEs in patients with IMSDs. Materials and Methods: Patients with IMSDs (e.g., autoimmune bullous diseases and vitiligo) who received AZA for ≥ 4 weeks were included. Data on clinical features, laboratory findings including NUDT15 and TPMT testing, AZA treatment regimens, and AZA‐associated AEs were reviewed and analyzed. Results: Among 103 patients, 18 developed AEs: 13 with myelotoxicity alone, 4 with hepatotoxicity alone, and one with both. The prevalence of NUDT15 and TPMT variants was 16.5% and 2.9%, respectively. In multivariate analysis, both NUDT15 and TPMT variants were significantly associated with AZA‐induced myelotoxicity (OR = 13.56, 95%CI = 2.43–75.64, and p = 0.003 and OR = 42.65, 95%CI = 1.40–1300.13, and p = 0.031, respectively). However, none were significantly related to hepatotoxicity. For AZA‐induced myelotoxicity screening, isolated NUDT15 and TPMT tests are low in sensitivity (LR+ = 4.45, 95%CI = 2.03–9.75, sensitivity 50.0%, and specificity 88.8% and LR+ = 12.70, 95%CI = 1.23–131.00, sensitivity 14.3%, and specificity 98.9%, respectively). While the combination of both tests increases screening ability (LR+ = 5.72, 95%CI = 2.83–11.50, sensitivity 64.3%, and specificity 88.8%). Conclusion: NUDT15 is more common than TPMT variants in Thais. In addition to TPMT, NUDT15 testing should be performed before the initiation of AZA to prevent AZA‐induced myelotoxicity in patients with IMSDs.


  • Open Access

    Clinicopathological Characteristics of Lichenoid Drug Eruption: A 17-Year Retrospective Study

    by Pichamon Promsena, Wimolsiri Iamsumang, Suthinee Rutnin

    Purpose: This study aims to characterize the etiology, clinicopathological features, laboratory findings, management strategies, and clinical outcomes of patients diagnosed with lichenoid drug eruption (LDE). Patients and Methods: A retrospective review was conducted on all biopsy-confirmed LDE cases from January 2008 to October 2024. Data collection included clinical characteristics, causative medications, histopathological as well as laboratory findings, and therapeutic responses. Results: Of the 34 patients, half were male, with a mean age of 65.1 years. LDE most commonly presented as erythematous to violaceous lesions, appearing as patches and plaques, predominantly on the extremities. Histopathology showed lichenoid infiltrates in all cases, with focal infiltration in 58.8%. Parakeratosis was present in 17.7%. Necrotic keratinocytes were found in the basal layer in 82.4% and in the spinous layer in 38.2% of cases. Eosinophilic infiltration was observed in approximately one-third of patients. The most common offending agents were calcium channel blockers (CCBs) (42.5%), followed by statins (25.8%). The median latency period from drug initiation to symptom onset was 10.1 months (interquartile range [IQR] 3.0– 45.5). Discontinuation of the causative agent combined with topical corticosteroid therapy resulted in clinical improvement in 73.5% of patients, with a median resolution time of 56 days (IQR 28.0– 77.0). Conclusion: Antihypertensive drugs, especially CCBs, were the most frequently implicated triggers of LDE. In addition to lichenoid dermatitis, eosinophilic infiltration served as a key histopathological hallmark of this condition. Timely identification and withdrawal of the causative medication, combined with appropriate treatment, are essential for achieving favorable clinical outcomes.


  • Allergic Contact Dermatitis to Acrylates in Samsung Galaxy® Earbuds: A Case Report

    by Wimolsiri Iamsumang, Pranee Svetvilas, Ploychompoo Srisuwanwattana, Nathathai Pratumchart, Penpun Wattanakrai

  • Open Access

    p‐Phenylenediamine‐Free Hair Dye?—Misleading Labelling Causing Allergic Contact Dermatitis

    by Wimolsiri Iamsumang, Kevin Bertilsson, Jakob Dahlin, Pichamon Promsena, Ploychompoo Srisuwanwattana, Pranee Svetvilas, Penpun Wattanakrai, Annarita Antelmi, Cecilia Svedman, Thanisorn Sukakul

    We report three cases of contact allergy to a mislabelled hair dye product. A hair dye product labelled as p‐phenylenediamine‐free has been found to contain p‐phenylenediamine by a chemical analysis at the level above the limits allowed in the product.


  • Open Access

    D-Penicillamine-Induced Stevens–Johnson Syndrome in a Patient with Gold Cyanide Intoxication: A Case Report

    by Tanaporn Anuntrangsee, Kumutnart Chanprapaph, Wimolsiri Iamsumang

    D-penicillamine is used as the mainstay of chelation therapy for Wilson’s disease and for heavy metal intoxication. D-penicillamine itself has been noted to cause several systemic side effects as well as symptoms related to the skin. Common cutaneous side effects such as acute hypersensitivity reactions, elastic fiber abnormalities, and bullous diseases have been occasionally described. Herein, we report a case of a 23-year-old Thai female with gold intoxication who developed Stevens–Johnson syndrome (SJS) following the treatment of D-penicillamine. To our knowledge, D-penicillamine-induced SJS is exceptionally rare. To raise awareness of potentially fatal cutaneous adverse drug reaction triggered by D-penicillamine, published literature regarding SJS induced by this agent has also been reviewed. D-penicillamine should be regarded as a possible culprit in patients presenting with SJS following D-penicillamine administration and should be promptly discontinued.


  • Open Access

    Panitumumab-Induced Periorbital Dermatitis: A Case Report

    by Napapat Pongbangpho, Kumutnart Chanprapaph, Wimolsiri Iamsumang

    Panitumumab is a recombinant, fully humanized immunoglobulin G2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the first- and second-line treatment of advanced wild-type KRAS colorectal cancer. Although common cutaneous side effects include acneiform dermatitis, folliculitis, and xerosis, ocular toxicities have occasionally been reported. Herein, we report the case of an 81-year-old Thai female with chemorefractory advanced stage sigmoid colon cancer who developed isolated periorbital dermatitis following treatment with panitumumab plus modified FOLFOX6. The cutaneous adverse reaction recurred after subsequent infusions; however, it was alleviated by topical therapy. To our knowledge, panitumumab-induced periorbital dermatitis is exceptionally rare. To raise awareness of potential periocular cutaneous side effects in patients taking EGFR inhibitors, the published literature regarding periorbital dermatitis induced by these agents has also been reviewed in this article. Periorbital dermatitis should be considered as a potential cutaneous reaction following panitumumab administration, and should be promptly treated.


  • Open Access

    Cutaneous Methotrexate-Related Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review

    by Chaninan Kositkuljorn, Suthinee Rutnin, Teerapong Rattananukrom, Teeraya Puavilai, Burana Khiankaew, Paisarn Boonsakan, Wimolsiri Iamsumang

    Methotrexate-related lymphoproliferative disorders (MTX-LPDs) are immunodeficiency diseases following methotrexate (MTX) administration, mainly occurring in rheumatoid arthritis patients. Although uncommon, MTX-LPDs have been reported in some patients with psoriasis, dermatomyositis, and cutaneous T-cell lymphoma (CTCL) who received MTX. Granulomatous mycosis fungoides (GMF) is a rare subtype of cutaneous T-cell lymphoma, where MTX is one of the treatment options in recalcitrant cases. Herein, we report a case of a 72-year-old female patient with GMF who additionally developed cutaneous Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) during MTX treatment. According to the 5th edition of the WHO classification of Haematolymphoid Tumors (WHO-HAEM), this condition is currently categorized as “lymphoma arising in immunodeficiency/dysregulation”. In this article, we also reviewed published literature on cutaneous MTX-LPDs in the setting of CTCL. This entity should be considered in cases of new, atypical skin nodules and/or plaques in CTCL patients receiving long-term MTX treatment.


  • Open Access

    Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy

    by Ploysyne Rattanakaemakorn, Prinpat Pinyowiwat, Wimolsiri Iamsumang, Kumutnart Chanprapaph, Poonkiat Suchonwanit

    Background: The use of methotrexate-acitretin (MTX-ACI) combination therapy in treating psoriasis has been limited due to concerns related to hepatic fibrosis. However, in vitro evidence revealed a protective effect of acitretin in methotrexate (MTX)-induced liver fibrosis. Objective: This study aimed to compare the real-life incidence of hepatic fibrosis in patients with psoriasis receiving MTX-ACI and MTX monotherapy and to investigate factors associated with hepatic fibrosis in MTX-exposed patients. Methods: A retrospective cohort study was conducted based on a real-life registry containing data on patients with psoriasis who were administered MTX-ACI or MTX between 2008 and 2019 and underwent transient elastography according to cumulative MTX dose of 1.0– 1.5 g and/or 3.5– 4.0 g. Time-to-event analysis was performed to determine the cumulative incidence, incidence rate, and factors potentially affecting the occurrence of hepatic fibrosis. Results: Of the 160 patients, 32 (20%) were treated with MTX-ACI, and 128 (80%) with MTX alone. Four patients (12.5%) in MTX-ACI group and 21 (16.4%) in MTX group developed hepatic fibrosis (p = 0.59). There was no statistically significant difference in cumulative incidence (16% in MTX-ACI vs 17% in MTX, p = 0.89) and incidence rate (37 cases per 1000 person-year in MTX-ACI vs 23 cases per 1000 person-year in MTX; hazard ratio [HR] = 1.07; p = 0.90) of hepatic fibrosis between the two groups. Diabetes and obesity were identified as significant factors associated with hepatic fibrosis (adjusted HR = 2.40, 95% confidence interval [CI]: 1.05– 5.51; p = 0.04 and adjusted HR = 3.28, 95% CI: 1.18– 9.16; p = 0.02, respectively) regardless of the cumulative MTX dose. Conclusion: The incidence of hepatic fibrosis in a real-life clinical situation, determined by transient elastography in patients with psoriasis receiving MTX-ACI, was not increased compared to those receiving MTX monotherapy. Type 2 diabetes mellitus and obesity were identified as risk factors of hepatic fibrosis; hence, patients with these factors receiving long-term MTX therapy should be regularly monitored for this particular event.


  • Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature

    by Poonkiat Suchonwanit, Wimolsiri Iamsumang, Kanchana Leerunyakul

    Background: Androgenetic alopecia (AGA) is a frequently encountered dermatological concern that impacts a patient’s self-esteem and quality of life. Finasteride is a selective 5-alpha reductase inhibitor that has been approved for the treatment of male AGA and the off-label use in female pattern hair loss (FPHL); however, its adverse effects may limit its use. Topical finasteride is a new formulation that aims to decrease complications caused by oral administration. Objective: This review assesses the pharmacology, current therapeutic use, and safety of topical finasteride for the treatment of AGA and FPHL. Methods: A PubMed search was conducted to include all English language articles on topical finasteride from January 1992 to January 2020. Results: A total of 33 articles including 28 topical finasteride related articles and five AGA related articles were included in this review. Multiple studies on topical finasteride as the treatment for male AGA and FPHL showed positive results with a favorable safety profile. Conclusions: Topical finasteride is a promising therapeutic option. We emphasize the importance of continued research for the establishment of a novel therapeutic agent.